EP4103705A4 - Éditeurs de nucléobases et leurs procédés d'utilisation - Google Patents

Éditeurs de nucléobases et leurs procédés d'utilisation Download PDF

Info

Publication number
EP4103705A4
EP4103705A4 EP21753734.9A EP21753734A EP4103705A4 EP 4103705 A4 EP4103705 A4 EP 4103705A4 EP 21753734 A EP21753734 A EP 21753734A EP 4103705 A4 EP4103705 A4 EP 4103705A4
Authority
EP
European Patent Office
Prior art keywords
methods
nucleobase editors
nucleobase
editors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21753734.9A
Other languages
German (de)
English (en)
Other versions
EP4103705A1 (fr
Inventor
Renzhi HAN
Li Xu
Yandi GAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of EP4103705A1 publication Critical patent/EP4103705A1/fr
Publication of EP4103705A4 publication Critical patent/EP4103705A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04002—Adenine deaminase (3.5.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04003—Guanine deaminase (3.5.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21753734.9A 2020-02-14 2021-02-12 Éditeurs de nucléobases et leurs procédés d'utilisation Withdrawn EP4103705A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976590P 2020-02-14 2020-02-14
PCT/US2021/017868 WO2021163492A1 (fr) 2020-02-14 2021-02-12 Éditeurs de nucléobases et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP4103705A1 EP4103705A1 (fr) 2022-12-21
EP4103705A4 true EP4103705A4 (fr) 2024-02-28

Family

ID=77292836

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21753734.9A Withdrawn EP4103705A4 (fr) 2020-02-14 2021-02-12 Éditeurs de nucléobases et leurs procédés d'utilisation

Country Status (3)

Country Link
US (2) US12416001B2 (fr)
EP (1) EP4103705A4 (fr)
WO (1) WO2021163492A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024303631A1 (en) * 2023-06-15 2025-12-11 Beam Therapeutics Inc. Methods and compositions for treating alpha-1 antitrypsin deficiency
WO2025038955A1 (fr) * 2023-08-16 2025-02-20 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Systèmes et procédés pour améliorer la sécurité d'une thérapie génique médiée par aav à intéine divisée
WO2025221785A1 (fr) * 2024-04-15 2025-10-23 Mayo Foundation For Medical Education And Research Méthodes et substances pour traiter une polykystose rénale
WO2025260086A1 (fr) * 2024-06-14 2025-12-18 President And Fellows Of Harvard College Édition de base site -spécifique in vivo

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218166A1 (fr) * 2017-05-25 2018-11-29 The General Hospital Corporation Utilisation de désaminases clivées pour limiter la désamination hors cible non désirée d'édition de bases
WO2019092042A1 (fr) * 2017-11-10 2019-05-16 Novozymes A/S Protéine cas9 sensible à la température
WO2019120283A1 (fr) * 2017-12-21 2019-06-27 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Procédé d'édition de bases chez les plantes
WO2019168953A1 (fr) * 2018-02-27 2019-09-06 President And Fellows Of Harvard College Variants de cas9 évolués et leurs utilisations
WO2019226953A1 (fr) * 2018-05-23 2019-11-28 The Broad Institute, Inc. Éditeurs de bases et leurs utilisations
WO2020010083A1 (fr) * 2018-07-05 2020-01-09 The Regents Of The University Of California Compositions et méthodes pour administrer de l'arn à une cellule
WO2020028823A1 (fr) * 2018-08-03 2020-02-06 Beam Therapeutics Inc. Éditeurs de nucléobase multi-effecteur et leurs méthodes d'utilisation pour modifier une séquence cible d'acide nucléique
WO2020033083A1 (fr) * 2018-08-10 2020-02-13 Cornell University Éditeurs de base optimisés permettant une édition efficace dans des cellules, des organoïdes et des souris

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102622411B1 (ko) * 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
KR20230125856A (ko) * 2016-12-23 2023-08-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Pcsk9의 유전자 편집
US12390514B2 (en) * 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3676376B1 (fr) * 2017-08-30 2025-01-15 President and Fellows of Harvard College Éditeurs de bases à haut rendement comprenant une gam
AU2019265019B2 (en) * 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
KR20250133482A (ko) * 2018-05-11 2025-09-05 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
WO2020160517A1 (fr) * 2019-01-31 2020-08-06 Beam Therapeutics Inc. Éditeurs de nucléobase ayant une désamination hors cible réduite et leurs méthodes d'utilisation pour modifier une séquence cible de nucléobase
US11946040B2 (en) * 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
WO2020168088A1 (fr) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions et procédés pour traiter la glycogénose de type 1a
CN110526993B (zh) 2019-03-06 2020-06-16 山东舜丰生物科技有限公司 一种用于基因编辑的核酸构建物
CN110029096B (zh) 2019-05-09 2023-05-12 上海科技大学 一种腺嘌呤碱基编辑工具及其用途
WO2021042062A2 (fr) * 2019-08-30 2021-03-04 Joung J Keith Éditeurs combinatoires d'adénine et de cytosine à base d'adn
US20210301269A1 (en) * 2020-01-22 2021-09-30 New York Genome Center, Inc. Recombinant crispr-cas9 nucleases with altered pam specificity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218166A1 (fr) * 2017-05-25 2018-11-29 The General Hospital Corporation Utilisation de désaminases clivées pour limiter la désamination hors cible non désirée d'édition de bases
WO2019092042A1 (fr) * 2017-11-10 2019-05-16 Novozymes A/S Protéine cas9 sensible à la température
WO2019120283A1 (fr) * 2017-12-21 2019-06-27 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Procédé d'édition de bases chez les plantes
WO2019168953A1 (fr) * 2018-02-27 2019-09-06 President And Fellows Of Harvard College Variants de cas9 évolués et leurs utilisations
WO2019226953A1 (fr) * 2018-05-23 2019-11-28 The Broad Institute, Inc. Éditeurs de bases et leurs utilisations
WO2020010083A1 (fr) * 2018-07-05 2020-01-09 The Regents Of The University Of California Compositions et méthodes pour administrer de l'arn à une cellule
WO2020028823A1 (fr) * 2018-08-03 2020-02-06 Beam Therapeutics Inc. Éditeurs de nucléobase multi-effecteur et leurs méthodes d'utilisation pour modifier une séquence cible d'acide nucléique
WO2020033083A1 (fr) * 2018-08-10 2020-02-13 Cornell University Éditeurs de base optimisés permettant une édition efficace dans des cellules, des organoïdes et des souris

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021163492A1 *

Also Published As

Publication number Publication date
US20230116627A1 (en) 2023-04-13
US20260071202A1 (en) 2026-03-12
EP4103705A1 (fr) 2022-12-21
US12416001B2 (en) 2025-09-16
WO2021163492A1 (fr) 2021-08-19

Similar Documents

Publication Publication Date Title
EP4412606A4 (fr) Inhibiteurs de pi3k-alpha et leurs procédés d'utilisation
EP4189088A4 (fr) Compositions d'édition dépendant d'adar et leurs procédés d'utilisation
EP4244358A4 (fr) Compositions d'édition d'arn et procédés d'utilisation
EP4192863A4 (fr) Molécules de liaison à il2rg et procédés d'utilisation
EP4225373A4 (fr) Anticorps anti-dectine-1 et leurs méthodes d'utilisation
EP4103705A4 (fr) Éditeurs de nucléobases et leurs procédés d'utilisation
EP4208548A4 (fr) Inhibiteurs de dux4 et leurs méthodes d'utilisation
EP4153743A4 (fr) Arn interagissant avec piwi dérivé d'exosomes et méthodes d'utilisation associées
EP4090685A4 (fr) Anticorps anti-gal3 et méthodes d'utilisation
EP3983386A4 (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
EP4009777A4 (fr) Facteur de transcription nterf221 et ses procédés d'utilisation
EP4192852A4 (fr) Molécules de liaison à l'il10ra et procédés d'utilisation
EP4413147A4 (fr) Variants de capside et leurs procédés d'utilisation
EP4110317A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP4399196A4 (fr) Inhibiteurs de pi3k-alpha et leurs procédés d'utilisation
EP4127188A4 (fr) Lymphocytes b modifiés et méthodes pour les utiliser
EP3941909A4 (fr) Inhibiteurs de pi4-kinase et leurs procédés d'utilisation
EP4423081A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP4358954A4 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
EP4142740A4 (fr) Compositions et leurs méthodes d'utilisation
EP4422681A4 (fr) Vaccin contre un norovirus et méthodes d'utilisation
EP4399524A4 (fr) Anticorps phospho-tau et méthodes d'utilisation
EP4263868A4 (fr) Nanoréseaux et leurs procédés d'utilisation
EP3983400C0 (fr) Composés quinazolinyles et procédés d'utilisation
EP4255503A4 (fr) Compositions et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230529

A4 Supplementary search report drawn up and despatched

Effective date: 20240129

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/86 20060101ALI20240123BHEP

Ipc: C12N 9/78 20060101ALI20240123BHEP

Ipc: C12N 9/22 20060101AFI20240123BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240817